Acute Myeloid Leukemia Clinical Trials in Basking Ridge, New Jersey
11 studies are recruiting for acute myeloid leukemia in Basking Ridge, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of …
- Stage
- Phase 2
- Ages
- 18 to 59
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 186 in total
- Run by
- National Cancer Institute (NCI)
-
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabi…
- Stage
- Phase 2
- Ages
- 18 to 59
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 226 in total
- Run by
- National Cancer Institute (NCI)
-
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrom…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 349 in total
- Run by
- National Cancer Institute (NCI)
-
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed in…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 227 in total
- Run by
- National Cancer Institute (NCI)
-
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younger patients who are considered unfit for standard treatment, …
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 136 in total
- Run by
- National Cancer Institute (NCI)
-
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment approach for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH mutation. Ma…
- Stage
- Phase 2
- Ages
- 60 and older
- Site
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
- Stage
- Phase 1
- Ages
- 1 and older
- Site
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study of Revumenib and Mezigdomide in People With Leukemia
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
- Stage
- Phase 1
- Ages
- 12 and older
- Site
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
- Locations
- 10 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Study of CRD3874-SI in People With Leukemia
The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 22 in total
- Run by
- National Cancer Institute (NCI)
-
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.